Measures for response assessment in HCC treatment

Abstract

The evolving treatment landscape of hepatocellular carcinoma (HCC) includes curative treatments such as ablation, resection, and transplantation, along with palliative interventions such as locoregional and systemic therapies. Evaluating the response to therapy is critical to planning the next intervention or follow-up needed, as well as for comparing the outcomes across the treatment options. Response to therapy can be measured using serum markers, through pathology, using imaging surrogates, and clinical response. This review provides a brief overview of these measures of treatment response and their relevance to HCC management.

Keywords

Minimally invasive / locoregional therapy / systemic therapy / treatment response / interventional radiology / interventional oncology / liver cancer / hepatocellular carcinoma

References

[1] Yang JD,Gores GJ,Plymoth A.A global view of hepatocellular carcinoma: trends, risk, prevention and management.Nat Rev Gastroenterol Hepatol2019;16:589-604 PMCID:PMC6813818

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] Huang A,Chung WY,Zhou J.Targeted therapy for hepatocellular carcinoma.Signal Transduct Target Ther2020;5:146 PMCID:PMC7419547

[4] Fan Y,Zheng H.Systemic therapy for hepatocellular carcinoma: current updates and outlook.J Hepatocell Carcinoma2022;9:233-63 PMCID:PMC8977221

[5] Galle PR,Kudo M.Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.Liver Int2019;39:2214-29

[6] Liu L,Jia J.The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization.Sci Rep2016;6:19851 PMCID:PMC4735679

[7] Piñero F,Pessôa MG.Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment.Cells2020;9:1370 PMCID:PMC7349517

[8] Johnson P,Dao DY.Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2022;19:670-81

[9] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol2018;15:599-616

[10] Casadei-Gardini A,Caputo F.Developments in predictive biomarkers for hepatocellular carcinoma therapy.Expert Rev Anticancer Ther2020;20:63-74

[11] Feng H,Li Z,Ren L.PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.BMC Cancer2021;21:401 PMCID:PMC8045263

[12] Tang SC,Lin ZW.Prognostic implications of preoperative, postoperative, and dynamic changes of alpha-fetoprotein and des-gamma (γ)-carboxy prothrombin expression pattern for hepatocellular carcinoma after hepatic resection: a multicenter observational study.Front Oncol2024;14:1425292 PMCID:PMC11188428

[13] Meyer T,Ma YT.Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol2017;2:565-75

[14] Chang Y,Young Jang J.Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma.Int J Mol Sci2020;21:8165 PMCID:PMC7662786

[15] Kudo M,Ikeda M.Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma.Liver Cancer2022;11:354-67 PMCID:PMC9294961

[16] Sohn W,Kim NH.Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.PLoS One2020;15:e0243780 PMCID:PMC7735598

[17] Hayashi M,Fujita M,Takahashi A.Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma.Jpn J Clin Oncol2020;50:36-43

[18] Zhang H,Wu W.Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.J Exp Clin Cancer Res2021;40:184 PMCID:PMC8178863

[19] Kudo M.Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma.Cancers2020;12:1089 PMCID:PMC7281246

[20] Chen SC,Chen MH.Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.BMC Cancer2022;22:55 PMCID:PMC8753926

[21] Finn RS,Zhu AX.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.J Clin Oncol2020;38:2960-70 PMCID:PMC7479760

[22] Eng C, Kim TW, Bendell J, et al; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2019;20:849-61.

[23] Shen KY,Xie SZ.Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.J Hematol Oncol2024;17:25 PMCID:PMC11057182

[24] Cheng AL,Ikeda M.Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022;76:862-73

[25] Sarwar A,Hassan L.Factors associated with complete pathologic necrosis of hepatocellular carcinoma on explant evaluation after locoregional therapy: a national analysis using the UNOS database.AJR Am J Roentgenol2023;220:727-35

[26] Frenette CT,Stark J.Conventional TACE and drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant pathologic response.Transplantation2014;98:781-7

[27] Shim JH,Kim SO.Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.Radiology2012;262:708-18

[28] Wu ZJ,Chang X.Type of necrosis influences prognosis in hepatocellular carcinoma after the first transarterial chemoembolization.Med Sci Monit2021;27:e929884 PMCID:PMC8120908

[29] Malone ER,Sabatini PJB,Siu LL.Molecular profiling for precision cancer therapies.Genome Med2020;12:8 PMCID:PMC6961404

[30] Kulik L,Zaiem F.Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis.Hepatology2018;67:381-400

[31] Lencioni R,Torres F.Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.J Hepatol2017;66:1166-72

[32] Mendiratta-Lala M,Shampain K.MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review.Radiol Imaging Cancer2020;2:e190024 PMCID:PMC7983779

[33] Zhao Y,Bai W.Which criteria applied in multi-phasic CT can predict early tumor response in patients with hepatocellular carcinoma treated using conventional TACE: RECIST, mRECIST, EASL or qEASL?.Cardiovasc Intervent Radiol2018;41:433-42 PMCID:PMC5803331

[34] Choi MH,Oh SN.Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization.Acad Radiol2018;25:1363-73

[35] Chapiro J,Duran R,Geschwind JF.Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.Expert Rev Anticancer Ther2015;15:199-205 PMCID:PMC4304995

[36] Hennedige T.Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring.Cancer Imaging2013;12:530-47 PMCID:PMC3666429

[37] Fournier L,Regge D.Twenty years on: RECIST as a biomarker of response in solid tumours an EORTC imaging group - ESOI joint paper.Front Oncol2021;11:800547 PMCID:PMC8784734

[38] Seyal AR,Velichko YS,Yaghmai V.Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.Acad Radiol2014;21:950-7

[39] Llovet JM,Villanueva A.Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival.J Hepatol2019;70:1262-77

[40] Zhao F.Surrogate end points and their validation in oncology clinical trials.J Clin Oncol2016;34:1436-7

[41] Yau T,Finn RS.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022;23:77-90

[42] Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.

[43] Granito A,Lalanne C.Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.World J Gastroenterol2021;27:2994-3009 PMCID:PMC8192285

[44] Cannella R,da Fonseca L,Rimola J.Immunotherapy-based treatments of hepatocellular carcinoma: AJR expert panel narrative review.AJR Am J Roentgenol2022;219:533-46

[45] Seymour L, Bogaerts J, Perrone A, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-52. PMCID:PMC5648544

[46] Wahl RL,Kasamon Y.From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors.J Nucl Med2009;50 Suppl 1:122S-50S PMCID:PMC2755245

[47] Storto G,Salvatore M.[18F]FDG-PET-CT for early monitoring of tumor response: when and why.Q J Nucl Med Mol Imaging2009;53:167-80

[48] Kielar A,Lewis S.Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.Abdom Radiol2018;43:218-30 PMCID:PMC5771991

[49] Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-date role of CT/MRI LI-RADS in hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:513-27 PMCID:PMC8180267

[50] Minami Y,Kudo M.Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.World J Gastroenterol2014;20:4160-6 PMCID:PMC3989952

[51] Granata V,Fusco R.Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma.Infect Agent Cancer2021;16:53 PMCID:PMC8287696

[52] Maas M,Gaubert JY.Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice.Insights Imaging2020;11:83 PMCID:PMC7366866

[53] Yaghmai V,Kim E,Siddiqui NA.Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.AJR Am J Roentgenol2013;201:80-96

[54] Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular carcinoma: diagnosis, treatment algorithms, and imaging appearance after transarterial chemoembolization.J Clin Transl Hepatol2018;6:175-88 PMCID:PMC6018317

[55] Vogl TJ,Elhawash E.Feasibility of diffusion-weighted magnetic resonance imaging in evaluation of early therapeutic response after CT-guided microwave ablation of inoperable lung neoplasms.Eur Radiol2022;32:3288-96 PMCID:PMC9038861

[56] Zhang W,Wang W,Sun QL.Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.BMC Cancer2019;19:1041 PMCID:PMC6833151

[57] Kloeckner R,Biesterfeld S,Dueber C.MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.Cardiovasc Intervent Radiol2010;33:532-40

[58] Sacco R,Marceglia S.Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives.World J Gastroenterol2015;21:6518-25 PMCID:PMC4458762

[59] Ma Y,Dong Q,Zhang J.How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.Am J Cancer Res2019;9:1546-53 PMCID:PMC6726978

[60] Chou R,Fu R.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis.Ann Intern Med2015;162:697-711

[61] Bruix J,Reig M.Insights into the success and failure of systemic therapy for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2019;16:617-30

[62] Tsujita Y,Ueshima E.Evaluation and prediction of treatment response for hepatocellular carcinoma.Magn Reson Med Sci2023;22:209-20 PMCID:PMC10086401

[63] Hwang YJ,Park H,Lee K.Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment.J Pathol Transl Med2021;55:338-48 PMCID:PMC8476315

[64] Afaq A,Koh DM.Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?.Cancer Imaging2010;10 Spec no A:S179-88 PMCID:PMC2967137

[65] Gluskin JS,Monti S,Mannelli L.Hepatocellular carcinoma and diffusion-weighted MRI: detection and evaluation of treatment response.J Cancer2016;7:1565-70 PMCID:PMC4964141

[66] Stefanini B,Chen R.TKIs in combination with immunotherapy for hepatocellular carcinoma.Expert Rev Anticancer Ther2023;23:279-91

[67] Liu W,Shen K.Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma.Med Oncol2023;40:251

[68] Wang E,Bai W.Tumor hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and sorafenib for intermediate hepatocellular carcinoma.BMC Cancer2019;19:409 PMCID:PMC6492437

[69] Andrade RJ.Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice.Liver Int2020;40:6-17

[70] Gaba RC, Lokken RP, Hickey RM, et al; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol 2017;28:1210-23.e3.

[71] Kirchner T,Werncke T.Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.Abdom Radiol2019;44:1554-61

[72] Eltawil KM,Abdolell M.Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study.HPB2012;14:341-50 PMCID:PMC3384854

[73] Guo T,Liu P.Identifying the best anticancer agent combination in tace for HCC patients: a network meta-analysis.J Cancer2018;9:2640-9 PMCID:PMC6072806

[74] Celsa C,Enea M.Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?.Liver Int2021;41:1105-16

[75] Cammarota A,Pressiani T,Rimassa L.Assessment and monitoring of response to systemic treatment in advanced hepatocellular carcinoma: current insights.J Hepatocell Carcinoma2022;9:1011-27 PMCID:PMC9482774

[76] Cardarelli-Leite L,Klass D.Current locoregional therapies and treatment strategies in hepatocellular carcinoma.Curr Oncol2020;27:S144-51 PMCID:PMC7739520

[77] Chen Z,Hu M.Recent progress in treatment of hepatocellular carcinoma.Am J Cancer Res2020;10:2993-3036 PMCID:PMC7539784

[78] Yang K,You YK.Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response.HPB2019;21:1718-26

[79] Choi JY,Sirlin CB.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.Radiology2014;273:30-50 PMCID:PMC4263770

[80] Deutsch JS,Thompson E.Association between pathologic response and survival after neoadjuvant therapy in lung cancer.Nat Med2024;30:218-28 PMCID:PMC10803255

[81] Sun BY,Guan RY.Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma.World J Surg Oncol2022;20:189 PMCID:PMC9178852

[82] Liu SC,Huang JY.Predicting microvascular invasion in hepatocellular carcinoma: a deep learning model validated across hospitals.Cancer Imaging2021;21:56 PMCID:PMC8501676

[83] Zhang Y,Ye Q.Preoperative prediction of microvascular invasion in hepatocellular carcinoma via multi-parametric MRI radiomics.Front Oncol2021;11:633596 PMCID:PMC7968223

[84] Stark S,Savic LJ.Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer.Sci Rep2020;10:18026 PMCID:PMC7582153

[85] García-Figueiras R,Luna A.Assessing immunotherapy with functional and molecular imaging and radiomics.Radiographics2020;40:1987-2010